Reporting owner · CIK 0001853327

Burrows Scott L

Visual SEC Form 4 history across 1 companies, 8 transactions and 2 filings.

CFOChief Financial OfficerSpyre Therapeutics, Inc.
Open-market mix
Latest filingSep 04, 2026, 01:33 AM
Filings2Form 4 records
Buying$00 purchases
Selling$2.3M5 sales
Net value−$2.3MBuys minus sells
Companies12 securities
Most recentSep 02, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Jan 255Sep 26

Net value flow

Buys minus sells

Jan 25
$0
Sep 26
−$2.3M

Transaction texture

Ownership and ticket size

Average P/S size$456.8K
Median P/S size$177.5K
Direct8
Indirect0
Sep 02, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Derivative Transactionfiling-context1Direct Ownershipfiling-context1Large Holdings Increaseholdings1

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Spyre Therapeutics, Inc. on Sep 02, 2026 valued at $1,629,029.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Spyre Therapeutics, Inc. on Sep 02, 2026 valued at $1,629,029.

Review SEC filing

Associated companies

Visual map of known reporting history

SYRESpyre Therapeutics, Inc.8 transactions · latest Sep 04, 2026, 01:33 AM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
SYREBurrows Scott L
CFO
exercise10b5-17.50k$0M
Derivative Transaction Direct Ownership 10b5-1 Detected
0.0%09/0409/01
SYREBurrows Scott L
CFO
sale10b5-118.2k-$162MS
Cluster Selling Direct Ownership Large Sale+2
0.0%09/0409/02
SYREBurrows Scott L
CFO
sale10b5-1200-$1.78MS
Cluster Selling Direct Ownership Repeat Seller+1
0.0%09/0409/01
SYREBurrows Scott L
CFO
sale10b5-12.01k-$17.7MS
Cluster Selling Direct Ownership Repeat Seller+1
0.0%09/0409/01
SYREBurrows Scott L
CFO
sale10b5-14.38k-$38.1MS
Cluster Selling Direct Ownership Repeat Seller+1
0.0%09/0409/01
SYREBurrows Scott L
CFO
sale10b5-1900-$7.76MS
Cluster Selling Direct Ownership 10b5-1 Detected
0.0%09/0409/01
SYREBurrows Scott L
CFO
exercise10b5-17.50k$10.8MM
Direct Ownership 10b5-1 Detected
0.0%09/0409/01
SYREBurrows Scott L
CFO
grant95.5k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—01/17/202501/15/2025

Burrows Scott L Insider Activity FAQ

SEC Form 4 context

Who is Burrows Scott L?

Burrows Scott L is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001853327.

Which companies has Burrows Scott L reported transactions for?

Spyre Therapeutics, Inc.

When was Burrows Scott L's latest insider buy?

No open-market insider purchase is available for this period.

When was Burrows Scott L's latest insider sale?

sale at Spyre Therapeutics, Inc. on Sep 02, 2026 valued at $1,629,029.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.